An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes - PubMed (original) (raw)
An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes
M Probst-Kepper et al. J Exp Med. 2001.
Abstract
We show that cytotoxic T lymphocytes (CTLs) infiltrating a kidney tumor recognize a peptide encoded by an alternative open reading frame (ORF) of the macrophage colony-stimulating factor (M-CSF) gene. Remarkably, this alternative ORF, which is translated in many tumors concurrently with the major ORF, is also translated in some tissues that do not produce M-CSF, such as liver and kidney. Such a dissociation of the translation of two overlapping ORFs from the same gene is unexpected. The antigenic peptide encoded by the alternative ORF is presented by human histocompatibility leukocyte antigen (HLA)-B*3501 and has a length of 14 residues. Peptide elution indicated that tumor cells naturally present this 14 mer, which is the longest peptide known to be recognized by CTLs. Binding studies of peptide analogues suggest that it binds by its two extremities and bulges out of the HLA groove to compensate for its length.
Figures
Figure 1
Lytic activity of CTL clone 403A/9. Targets were: autologous tumor cells LB1047-RCC, allogeneic HLA-B35–positive renal carcinoma cells HA7-RCC and LE9211-RCC, and the corresponding EBV-transformed B cell lines LB1047-EBV, HA7-EBV, and LE9211-EBV. NK target K562 was also used as control. All target cells were treated with 100 U/ml IFN-γ 24 h before the test. Chromium release was measured after 4 h.
Figure 2
Isolation of a cDNA encoding the antigen recognized by CTL 403A/9. 293-EBNA cells were transfected transiently with cDNA 314 and with a plasmid construct encoding HLA-B*3501. CTL 403A/9 was added after 24 h and the amount of IFN-γ in the supernatant was measured 24 h later. LB1047-RCC cells were used as positive control.
Figure 4
Expression of the alt.M-CSF product in tubular kidney cells and in hepatocytes. Paraffin sections from: the renal tumor of patient LB1047 (A and B); a normal kidney biopsy from a graft donor (D and E); or a normal liver (G and H) were stained with either a rabbit control IgG (A, D, and G) or a rabbit antiserum raised against the alt.M-CSF polypeptide (B, E, and H). Cryosections from: the renal tumor of patient EB56 (C), a normal kidney sample from patient LB2043 (F), or a normal liver (I) were stained with a monoclonal antibody against M-CSF. Original magnifications: ×200 (A–C) and ×100 (D–I).
Figure 5
Recognition of normal kidney cells by CTL 403A/9. Short-term cell lines LB2046-PTEC and LB2043-PTEC (10,000 cells/well), which derive from proximal tubular epithelial cells (PTEC), were incubated with CTL 403A/9 (10,000/well), and the production of TNF in the supernatant was measured after 24 h. In the absence of CTL, LB2043-PTEC, and LB2046-PTEC produced 2 and 3 pg/ml TNF, respectively. As indicated, both lines were transiently transfected with HLA-B*3501, to ensure expression of the presenting molecule. Line LB2046-PTEC, which was already recognized by CTL 403A/9 in the absence of transfection, was later confirmed to express HLA-B35 naturally. The amount of M-CSF produced by the same cell lines was meas-ured by ELISA on culture supernatants and is indicated.
Figure 6
Elution of the natural peptide recognized by CTL 403A/9. (A) HPLC fractions of peptides eluted with acid from the HLA class I molecules of LB1047-RCC were tested for their ability to stimulate CTL 403A/9 after pulsing onto HLA-B35–positive target cells A110L-B35. The results of one representative experiment out of three are shown. (B) Synthetic peptide LPAVVGLSPGEQEY (150 pmol) was injected on the same HPLC column and its elution was monitored by UV absorption. (C) 1 pmol of the synthetic peptide was injected on the same column and the fractions were tested for CTL recognition as indicated in panel A.
Figure 3
Identification of the peptide recognized by CTL 403A/9. (A) Partial sequence of the 5′ end of the M-CSF cDNA, showing the alternative ORF (boxed) coding for a 25-amino acid polypeptide (alt.M-CSF), and the initial part of the major ORF which encodes the leader sequence and the first residues of the mature M-CSF, which starts at position +1. The arrow indicates the boundary between exon 1 and 2 (reference 46). The antigenic peptide in the alt.M-CSF sequence is shown in bold. (B) CTL recognition of cells transfected with minigenes containing the alternative ORF encoding alt.M-CSF. 293-EBNA cells were transfected with plasmids containing HLA-B*3501 and minigenes encoding either the full-length alt.M-CSF product of 25 amino acids or a truncated product containing the first 20 amino acids. CTL 403A/9 was added after 24 h and production of IFN-γ was measured 24 h later. (C) Recognition of peptide LPAVVGLSPGEQEY by CTL 403A/9. Chromium-labeled LB1047-EBV B cells were incubated 30 min at 37°C with the indicated peptides at various concentrations. CTL 403A/9 was added at an effector/target ratio of 10, and chromium release was measured after 4 h.
Figure 3
Identification of the peptide recognized by CTL 403A/9. (A) Partial sequence of the 5′ end of the M-CSF cDNA, showing the alternative ORF (boxed) coding for a 25-amino acid polypeptide (alt.M-CSF), and the initial part of the major ORF which encodes the leader sequence and the first residues of the mature M-CSF, which starts at position +1. The arrow indicates the boundary between exon 1 and 2 (reference 46). The antigenic peptide in the alt.M-CSF sequence is shown in bold. (B) CTL recognition of cells transfected with minigenes containing the alternative ORF encoding alt.M-CSF. 293-EBNA cells were transfected with plasmids containing HLA-B*3501 and minigenes encoding either the full-length alt.M-CSF product of 25 amino acids or a truncated product containing the first 20 amino acids. CTL 403A/9 was added after 24 h and production of IFN-γ was measured 24 h later. (C) Recognition of peptide LPAVVGLSPGEQEY by CTL 403A/9. Chromium-labeled LB1047-EBV B cells were incubated 30 min at 37°C with the indicated peptides at various concentrations. CTL 403A/9 was added at an effector/target ratio of 10, and chromium release was measured after 4 h.
Figure 3
Identification of the peptide recognized by CTL 403A/9. (A) Partial sequence of the 5′ end of the M-CSF cDNA, showing the alternative ORF (boxed) coding for a 25-amino acid polypeptide (alt.M-CSF), and the initial part of the major ORF which encodes the leader sequence and the first residues of the mature M-CSF, which starts at position +1. The arrow indicates the boundary between exon 1 and 2 (reference 46). The antigenic peptide in the alt.M-CSF sequence is shown in bold. (B) CTL recognition of cells transfected with minigenes containing the alternative ORF encoding alt.M-CSF. 293-EBNA cells were transfected with plasmids containing HLA-B*3501 and minigenes encoding either the full-length alt.M-CSF product of 25 amino acids or a truncated product containing the first 20 amino acids. CTL 403A/9 was added after 24 h and production of IFN-γ was measured 24 h later. (C) Recognition of peptide LPAVVGLSPGEQEY by CTL 403A/9. Chromium-labeled LB1047-EBV B cells were incubated 30 min at 37°C with the indicated peptides at various concentrations. CTL 403A/9 was added at an effector/target ratio of 10, and chromium release was measured after 4 h.
Similar articles
- A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. Wang RF, et al. J Immunol. 1998 Oct 1;161(7):3598-606. J Immunol. 1998. PMID: 9759882 - Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Wang RF, et al. J Exp Med. 1996 Mar 1;183(3):1131-40. doi: 10.1084/jem.183.3.1131. J Exp Med. 1996. PMID: 8642255 Free PMC article. - Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Wang RF, Rosenberg SA. Wang RF, et al. J Leukoc Biol. 1996 Sep;60(3):296-309. doi: 10.1002/jlb.60.3.296. J Leukoc Biol. 1996. PMID: 8830785 Review. - Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.
Boon T, Van Pel A, De Plaen E, Chomez P, Lurquin C, Szikora JP, Sibille C, Mariamé B, Van den Eynde B, Lethé B, et al. Boon T, et al. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:587-96. doi: 10.1101/sqb.1989.054.01.070. Cold Spring Harb Symp Quant Biol. 1989. PMID: 2700947 Review. No abstract available.
Cited by
- Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.
Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, Teo GC, da Veiga Leprevost F, Barnea E, Yu F, Admon A, Eisenbach L, Samuels Y, Schueler-Furman O, Levin Y, Nesvizhskii AI, Merbl Y. Kacen A, et al. Nat Biotechnol. 2023 Feb;41(2):239-251. doi: 10.1038/s41587-022-01464-2. Epub 2022 Oct 6. Nat Biotechnol. 2023. PMID: 36203013 Free PMC article. - Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ, Lee YH, Koo KC. Kim TJ, et al. Investig Clin Urol. 2022 Sep;63(5):486-498. doi: 10.4111/icu.20220103. Investig Clin Urol. 2022. PMID: 36067994 Free PMC article. Review. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Understanding small ORF diversity through a comprehensive transcription feature classification.
Guerra-Almeida D, Tschoeke DA, Nunes-da-Fonseca R. Guerra-Almeida D, et al. DNA Res. 2021 Sep 13;28(5):dsab007. doi: 10.1093/dnares/dsab007. DNA Res. 2021. PMID: 34240112 Free PMC article. Review. - Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
Xu Y, Miller CP, Warren EH, Tykodi SS. Xu Y, et al. Hum Vaccin Immunother. 2021 Jul 3;17(7):1882-1896. doi: 10.1080/21645515.2020.1870846. Epub 2021 Mar 5. Hum Vaccin Immunother. 2021. PMID: 33667140 Free PMC article. Review.
References
- Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 1999;17:739–779. - PubMed
- Mayrand S.-M., Green W.R. Non-traditionally derived CTL epitopesexceptions that prove the rules? Immunol. Today. 1998;19:551–556. - PubMed
- Skipper J.C.A., Kittlesen D.J., Hendrickson R.C., Deacon D.D., Harthun N.L., Wagner S.N., Hunt D.F., Engelhard V.H., Slingluff C.L.J. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 1996;157:5027–5033. - PubMed
- Meadows L., Wang W., den Haan J.M., Blokland E., Reinhardus C., Drijfhout J.W., Shabanowitz J., Pierce R., Agulnik A.I., Bishop C.E. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6:273–281. - PubMed
- Pierce R.A., Field E.D., den Haan J.M.M., Caldwell J.A., White F.M., Marto J.A., Wang W., Frost L.M., Blokland E., Reinhardus C. Cutting Edgethe HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J. Immunol. 1999;163:6360–6364. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous